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ABSTRACT
Objective: Surgical aortic valve replacement (AVR)
remains the gold standard therapy for severe aortic
stenosis. Long-term survival data following AVR is
required. Our objective was to provide a detailed
contemporary benchmark of long-term survival
following AVR among elderly patients (≥65 years) in
the UK.
Methods: We conducted a retrospective cohort study
of 1815 adult patients undergoing surgical AVR±
coronary artery bypass graft (CABG) surgery at a single
UK centre between 1996 and 2011. Our main outcome
was patient survival, which was assessed by linkage to
census records at the Office for National Statistics.
Results: The mean age of the cohort was 75 (±5.6)
years. Patients in the AVR alone group had a slightly
higher median survival of 10.9 (95% CI 10.5 to 11.8)
years than the AVR+CABG group which had a median
survival of 9.6 (95% CI 8.7 to 10.1) years (p=0.001 of
log-rank test (LRT) for equality of survivor functions).
The presence of chronic kidney disease, severely
impaired left ventricular function or being a current
smoker were each associated with a ≥50% increased
risk of long-term mortality. Comparison of our study
cohort patients and the reference (operation year, age
and gender matched) UK population suggested no
difference in survival probability up to 8 years
(p=0.55). However, for longer periods of follow-up, the
difference became increasingly significant (p<0.0001).
Conclusions: Long-term survival following surgical
AVR in patients over 65 years of age is excellent and
up to 8 years is comparable to the matched general
population.
INTRODUCTION
Aortic valve disease is the most common type
of valvular heart disease in Europe and
North America, occurring in 2–7% of the
population over 65 years of age.1 2 When
untreated, symptom progression is rapid and
lethal, with a median survival of <2 years in
those with heart failure symptoms.3 4 Medical
therapy is largely ineffective for the long-
term management of aortic valve disease,
and valve replacement remains the standard
of care in patients with an acceptable risk
proﬁle. Among the oldest patients and those
with a high burden of comorbidities, the
perioperative risk of surgical aortic valve
replacement (AVR) is often perceived to out-
weigh the potential long-term beneﬁts, with
a perception of high operable risk account-
ing for 30% of all non-operated patients with
symptomatic aortic stenosis (AS).5 Although
the perioperative risk associated with AVR
has been well studied, the long-term out-
comes after open AVR have not been well
described, making accurate assessment of the
beneﬁts of open AVR challenging in this
population.
Transcatheter delivery of aortic valve pros-
theses offers a potential treatment option in
high-risk patients and has been shown at
2-year follow-up to be superior to medical
therapy in non-operable patients and
KEY QUESTIONS
What is already known about this subject?
▸ Surgical aortic valve replacement (AVR) in
elderly patients has excellent short-term and
mid-term outcomes. The establishment of a
robust surgical benchmark of long-term survival
after open AVR is of increasing importance, par-
ticularly in the era of transcatheter aortic valve
implantation (TAVI).
What does this study add?
▸ This study provides long-term survival data for
patients over 65 years of age undergoing AVR
and compares this to the expected survival of the
general population. It demonstrates that long-
term survival in this patient group is excellent.
How might this impact on clinical practice?
▸ Outcomes following AVR in elderly patients are
excellent and, therefore, age should not be a
factor when considering patients for surgical
AVR. This study provides a benchmark for
ongoing trials of TAVI in intermediate-risk
patients with severe aortic stenosis.
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non-inferior to open valve replacement in high-risk
patients.6 7 As long-term transcatheter AVR outcomes
accrue, the establishment of a robust surgical bench-
mark of long-term survival after open AVR is of increas-
ing importance to inform prognosis and to aid clinical
and economic evaluations of new technologies.
The objective of this study was therefore to describe
in-hospital outcomes and long-term survival of patients
undergoing surgical AVR, to compare their survival with
the survival of the age-matched and gender-matched
section of the general population and to assess the asso-
ciation between mortality and speciﬁc high-risk
comorbidities.
METHODS
This was a retrospective cohort study of prospectively col-
lected data from consecutive patients undergoing AVR at
the Bristol Heart Institute, Bristol Royal Inﬁrmary, UK,
between April 1996 and December 2011. The study was
approved by the Clinical Audit Committee of the
University Hospitals Bristol National Health Service
Foundation Trust to meet ethical and legal require-
ments, and individual consent was waived. The data col-
lection form is entered in a database (Patient Analysis &
Tracking System; Dendrite Clinical Systems, London,
UK) and includes ﬁve sections that are ﬁlled in consecu-
tively by anaesthetists, surgeons, intensive care unit, high
dependency unit and ward nurses. Data entry is period-
ically checked for accuracy by independent database
managers.
Chronic kidney disease (CKD) was deﬁned as a base-
line serum creatinine of ≥200 μmol/L. Chronic lung
disease was deﬁned as chronic obstructive pulmonary
disease or asthma requiring bronchodilators or steroid
therapy. Diabetes mellitus was deﬁned as patients requir-
ing oral hypoglycaemic agents or subcutaneous insulin
therapy. Left ventricular (LV) systolic function was
deﬁned as normal (LV ejection fraction (LVEF) ≥52%),
mildly impaired (LVEF 41–51%), moderately impaired
(LVEF 30–40%) and severely impaired (LVEF <30%)
according to the American Society of Echocardiography
recommendations.8
Study population
The study cohort is a subset of the Bristol PATS data-
base, which contains 21 515 entries. The study cohort
included elderly patients (aged ≥65 years) who had
undergone either elective or urgent AVR operation with
or without coronary artery bypass graft (CABG) proced-
ure. Records were excluded if they involved multiple
valve procedures, other major non-valve-related opera-
tions (other than CABG), previous AVR and emergent
or salvage operations.
Patient subgroups
Because long-term outcomes are expected to vary
according to the burden of speciﬁc comorbidities,
several patient subgroups were prospectively identiﬁed
for analysis. For all analyses, patients were categorised by
procedure type (eg, isolated AVR, AVR+CABG) and age
(65–69, 70–79, ≥80 years). Other patient subgroups
included European System for Cardiac Operative Risk
Evaluation (EuroSCORE; low≤5, high≥5) and develop-
ment of a postoperative complication.
Study end point
Patient survival, which was the primary outcome of inter-
est for this study, was assessed by linkage to census
records at the Ofﬁce for National Statistics (ONS). Life
status (mortality) information for all patients was
obtained from the ONS up to 31 July 2013.
Comparison with the operation year-matched,
age-matched and gender-matched UK population
To establish a comparative population-based reference
survival curve, we generated a baseline Kaplan-Meier
(KM) curve for an age-matched, gender-matched and
year-matched patient population using the life tables of
ONS.9 For each patient in our cohort, we used the
annual mortality probabilities from the ONS life tables
to run Monte Carlo (MC) simulations for that indivi-
dual’s survival, starting from the year of operation and
advancing in yearly increments.10 The patient-level
events were then aggregated across the cohort to gener-
ate a ﬁnal aggregate KM curve, representing the
expected survival behaviour of the matched general
population. For each patient, 1000 MC runs were per-
formed to generate statistically sufﬁcient events and
produce a reliable baseline survival curve.
Statistical analysis
Descriptive statistics included mean±SD and percentages
to describe patient and operative characteristics in two
procedural groups, that is, those who underwent AVR
alone and those who underwent AVR+CABG. These pro-
cedural groups were compared using t test or χ2 test as
appropriate. Multiple logistic regression was used to esti-
mate the predictors of in-hospital and 30-day mortality.
Median survival times after surgery were measured for
various strata of patients. Log-rank test (LRT) was used
to evaluate the equality of the survivor functions.
Multivariable Cox proportional hazards (CPH) model
was used to estimate the HRs of long-term risk predic-
tors of mortality. The assumption of proportionality of
hazards was checked visually. For multiple logistic regres-
sion and CPH models, all the variables were included
initially and stepwise backward elimination approach was
used to arrive at the ﬁnal models. The predictors which
were examined for short-term and long-term risk models
included age at operation, gender, smoking status,
CABG procedure, LV function (LVF), history of chronic
lung disease and/or CKD, extracardiac arteriopathy, pre-
operative arrhythmia, being under hypertensive and/or
diabetic treatment as well as the EuroSCORE. We also
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performed univariate analysis and the p value threshold
was Bonferroni adjusted to account for multiple testing.
Statistical analyses including generation of the aggre-
gate KM curve using the simulated MC runs were per-
formed using Stata V.11.2 for Windows (StataCorp,
College Station, Texas, USA). MC simulations were per-
formed using R programming language (R Core Team.
R: A language and environment for statistical comput-
ing. Vienna, Austria: R Foundation for Statistical
Computing. 2014).
RESULTS
Study population
A cohort of 1815 adult patients underwent AVR for AS
between 1996 and 2011, including 967 who underwent
isolated AVR and 848 patients who underwent AVR with
concomitant CABG surgery (ﬁgure 1). They had a mean
age of 75 (±5.6) years, 1022 (56%) were male patients,
38 (2.1%) had CKD, 256 (14.1%) had chronic lung
disease and 107 (5.9%) had severely impaired LVF.
Patient and operative characteristics stratiﬁed by proced-
ure are shown in table 1. Thirty (1.7%) patients were
lost to long-term follow-up.
In-hospital outcomes
In-hospital outcomes are presented in table 2. A total of
68 (3.8%) patients died in hospital or within 30 days fol-
lowing the operation. Of them, 27 (1.5%) patients were
in the AVR group and 41 (2.3%) in the AVR+CABG
group. EuroSCORE >5 was a signiﬁcant predictor of
in-hospital/30-day mortality (OR 1.4 (95% CI 1.2 to
1.5), p<0.0001). Postoperative reoperation for bleeding
(8.6% vs 7.9%, p=0.048) and cerebrovascular accident
(CVA) (1.7% vs 0.7%, p=0.040) was signiﬁcantly higher
in the AVR alone group compared to patients
undergoing AVR+CABG. Conversely, the need for post-
operative haemoﬁltration was lower in the AVR group
than the AVR+CABG group, although this did not reach
statistical signiﬁcance (1.8% vs 3.2%, p=0.068; table 2).
Results of the univariate analysis are shown in online
supplementary table S1.
Long-term survival after AVR
Survival analysis included 5.4, 17.3 and 10 950.55 years
of median, maximum and total time at risk, respectively.
In total, 707 (38.9%) patients died during the follow-up
period, of which 356 (19.6%) underwent isolated AVR
and 351 (19.3%) underwent AVR+CABG. Patients in the
AVR alone group had a slightly higher median survival
of 10.9 (95% CI 10.5 to 11.8) years than the AVR+CABG
group which had a median survival of 9.6 (95% CI 8.7
to 10.1) years (p=0.001 of LRT for equality of survivor
functions).
Median survival times in the AVR alone group across
the age groups of ‘65–69’, ‘70–79’ and ‘80 or over’ were
15.1, 10.6 and 6.3 years, respectively. In the AVR+CABG
group, median survival times for the same age groups
were 12.5, 9.6 and 6.4 years, respectively. The difference
in survival of these six procedure age categories was sig-
niﬁcant (p<0.0001; ﬁgure 2). Median survival times for
AVR alone with no postoperative complication, AVR
alone with any complication, AVR+CABG with no com-
plication and AVR+CABG with any complication were
11.07, 7.02, 9.65 and 8.52, respectively. Median survival
times stratiﬁed by procedural groups, procedure and age
groups as well as procedure and EuroSCORE categories
are shown in table 3.
Table 4 shows HRs of the predictors of long-term mor-
tality. Age at operation, chronic lung disease, hyperten-
sion, diabetes mellitus, extracardiac arteriopathy and
preoperative arrhythmia were associated with increased
Figure 1 Bristol cardiac surgical
database cohort development
flow chart.
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risk of long-term mortality. However, CKD, poor LVF or
being a current smoker were each associated with a
≥50% increased risk of long-term mortality.
Comparison of our study cohort with the reference
(operation year, age and gender matched) UK popula-
tion suggested no difference in survival probability up to
8 years (p=0.55). However, for longer periods of
follow-up, the difference became increasingly signiﬁcant
(p<0.0001; ﬁgure 3). Moreover, the matched UK popula-
tion shows signiﬁcantly higher survival probability for
women (p<0.0001 for LRT). However, the survival advan-
tage of women no longer existed for aortic valve surgery
patients aged 65 years and over (p=0.71; ﬁgure 4). We
also stratiﬁed our analysis by procedural group. In the
AVR alone group, survival was not different from the
matched general population up to 9 years (p=0.11).
However, in the AVR+CABG group, survival matched the
general population only up to 7 years (p=0.14). After
these points, survival become signiﬁcantly worse com-
pared to their matched background population in both
groups (see online supplementary ﬁgure S1).
DISCUSSION
Main findings
Our report provides a detailed contemporary bench-
mark of long-term survival following AVR among older
patients in the UK. From our results, four important
ﬁndings emerge. First, long-term survival following AVR
among older patients is excellent and therefore age
should not be a factor in the decision for surgery.
Second, baseline CKD, severely impaired LVF and
current smoking status indicate particularly poor long-
term prognosis after surgical AVR. Third, development
of a postoperative complication such as CVA, haemoﬁl-
tration or re-exploration for bleeding reduced survival
compared to patients who did not develop any complica-
tion. Fourth, the female survival advantage over men no
longer exists in patients undergoing aortic valve surgery.
Comparison with existing literature
The expected survival of symptomatic patients with
severe AS who do not have surgery is 1–4 years.3 4
Surgical AVR improves this dismal prognosis and, as we
have shown in the present study, restores survival to that
expected of an age-matched and gender-matched
Table 1 AVR cohort characteristics stratified by procedure (AVR alone, AVR+CABG)
Characteristics Valve alone Valve+other p Value
Number of patients 967 848
Age at procedure 74.8 (5.6) 75.4 (5.7) 0.02
Male 457 (47.6%) 565 (66.6%) <0.0001
Cumulative bypass time 92.8 (27.3) 125.6 (38) <0.0001
Cumulative cross clamp time 67 (18.1) 87.2 (23.1) <0.0001
EuroSCORE 6.8 (1.9) 7.3 (2.1) <0.0001
Logistic EuroSCORE 0.079 (0.05) 0.095 (0.075) <0.0001
High EuroSCORE (>5) 720 (74.5%) 666 (78.5%) <0.0001
Aortic valve gradient (mm Hg) 55.1 (41.1) 43.8 (37.0) 0.53
Aortic valve (mechanical) 181 (18.7%) 149 (18.2%) 0.11
Severely impaired left ventricular function 49 (5.1%) 58 (6.9%) 0.68
Chronic kidney disease (SCr ≥200 µmol/L) 19 (2.0%) 19 (2.3%) 0.45
Chronic lung disease 142 (14.7%) 114 (13.4%) <0.0001
Number of grafts 0.0 (0.0%) 1.8 (1%) =0.21
Aortic valve size (mm)
17 6 (0.6%) 8 (0.9%)
19 249 (25.8%) 186 (21.9%)
21 394 (40.87%) 333 (40.1%)
23 233 (24.1%) 226 (26.6%)
25 61 (6.3%) 71 (8.4%)
27 19 (2.0%) 18 (2.1%)
29 2 (0.2%) 5 (0.6%)
Mean (SD) or %; t test and χ2 tests for comparing means and percentages, respectively.
AVR, aortic valve replacement; CABG, coronary artery bypass graft; EuroSCORE, European System for Cardiac Operative Risk Evaluation.
Table 2 Postoperative complications by procedure type
Postoperative
complication AVR AVR+CABG p Value
Number of patients 967 848
In-hospital death 27 (1.5%) 41 (2.3%) 0.022
Reoperation for
bleeding
54 (8.6%) 67 (7.9%) 0.048
Permanent stroke 15 (1.7%) 5 (0.7%) 0.040
Haemofiltration 16 (1.8%) 25 (3.2%) 0.068
AVR, aortic valve replacement; CABG, coronary artery bypass
graft.
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general population without AS at least up to 8 years of
follow-up.
Our ﬁndings are consistent with previous reports by
high-volume centres undertaking AVR in elderly
patients. A report published using the Society of
Thoracic Surgeons (STS) Adult Cardiac Surgery
Database of over 145 000 patients from over 1000 US
centres found a median survival of 13, 9 and 6 years in
patients undergoing isolated AVR aged 65–69, 70–79
and ≥80 years of age, respectively.11 For patients under-
going AVR+CABG, median survival for the same age
groups was 10, 8 and 6 years.11 Similarly, baseline CKD,
severely impaired LVF and being a current smoker have
all been associated with poor long-term survival follow-
ing surgical AVR.11 12
Transcatheter aortic valve implantation (TAVI) has
emerged as an alternative to surgical AVR in the treat-
ment of severe AS in inoperable or high-risk surgical
candidates. The PARTNER 1B trial has demonstrated
the signiﬁcant short-term and mid-term survival and
symptomatic beneﬁt of TAVI compared to medical
therapy in inoperable patients with severe AS.7 13
Figure 2 Long-term survival
after (A) AVR and (B) AVR
+CABG. Survival curves
(Kaplan-Meier estimates) are
presented with 95% CIs and are
stratified by age group. AVR,
aortic valve replacement; CABG,
coronary artery bypass graft.
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In high-risk surgical candidates (deﬁned as an STS risk
score of ≥10%), the PARTNER 1A trial demonstrated
TAVI to be equivalent to surgical AVR in terms of short-
term and mid-term mortality at 2 years.6 14 However,
TAVI did result in signiﬁcantly higher rates of stroke,
major vascular complications and paravalvular regurgita-
tion compared to surgical AVR. As a result, international
valve guidelines now recommend TAVI in patients who
have a prohibitive surgical risk and a predicted post-TAVI
survival of >12 months or who have a high surgical
risk.15
Of concern, however, is that TAVI is being extended to
low-risk and intermediate-risk surgical patients where no
compelling evidence for its efﬁcacy exists. For example,
in Germany, the use of TAVI has exploded with 89 TAVIs
performed per million population, the highest in
Table 3 Patient characteristics stratified by procedure (AVR alone, AVR+CABG), age, EuroSCORE and postoperative
complication
Number of patients Median survival (95% CI)
Entire cohort 1815 10.3 (9.8 to 10.6)
By procedure groups
AVR alone 967 10.9 (10.5 to 11.8)
AVR+CABG 848 9.6 (8.7 to 10.1)
By procedure and age groups
AVR alone (65–69) 226 15.1 (13.5, …)
AVR alone (70–79) 563 10.6 (10.1 to 11.6)
AVR alone (≥80) 178 6.3 (5.2 to 8.2)
AVR+CABG (65–69) 174 12.5 (11.2, …)
AVR+CABG (70–79) 485 9.6 (8.6 to 10.1)
AVR+CABG (≥80) 189 6.4 (5.2 to 8.2)
By procedure and EuroSCORE categories
AVR alone; low EuroSCORE 247 14.5 (13.8, …)
AVR alone; high EuroSCORE 720 9.9 (9.2 to 10.6)
AVR+CABG; low EuroSCORE 182 13.2 (10.7, …)
AVR+CABG; high EuroSCORE 666 8.7 (8 to 9.6)
By procedure groups with or without any postoperative complications*
AVR alone; no complication 881 11.07 (10.50 to 12.09)
AVR alone; any complication 86 7.02 (5.43 to 10.78)
AVR+CABG; no complication 743 9.65 (8.76 to 10.16)
AVR+CABG; any complication 105 8.52 (6.44, …)
*Postoperative haemofiltration, postoperative stroke and reoperation for bleeding.
AVR, aortic valve replacement; CABG, coronary artery bypass graft; EuroSCORE, European System for Cardiac Operative Risk Evaluation.
Table 4 Predictors of long-term mortality (Cox regression
survival analysis)
Risk factor HR p Value
Age at operation 1.1 (1.1 to 1.1) 0.000
Left ventricular
function
(Moderately
impaired)
1.2 (1.0 to 1.4) 0.119
(Severely
impaired)
1.6 (1.2 to 2.1) 0.002
Lung disease 1.3 (1.1 to 1.6) 0.005
Chronic kidney disease 1.8 (1.2 to 2.8) 0.010
Smoker (Former) 1.1 (1.0 to 1.3) 0.185
(Current) 1.5 (1.1 to 2.1) 0.015
Antihypertensive treatment 1.2 (1.0 to 1.4) 0.028
Antidiabetic treatment 1.3 (1.0 to 1.6) 0.056
Arteriopathy (extracardiac) 1.4 (1.1 to, 1.9) 0.016
Arrhythmia (preoperative) 1.4 (1.2 to 1.7) 0.000
‘Gender’ and ‘AVR+CABG versus AVR’ were not significant
predictors.
Figure 3 Comparison between Kaplan-Meier survival
estimates of Bristol aortic valve surgery patients and the
Monte Carlo-based generated Kaplan-Meier curve using the
matched ONS population. It appears that for a follow-up
period of <8 years, the difference between the survival
estimates is not significant (p=0.55) using log-rank test for
equality of survivor functions. However, for longer periods of
follow-up, the difference becomes increasingly significant with
p<0.0001 for the entire follow-up period. ONS, Office for
National Statistics.
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Europe.16 This is compared to the UK where TAVI use is
more regulated and therefore performs <20 implants
per million population.16 Increasing number of observa-
tional studies report the equivalence of TAVI to surgical
AVR in terms of in-hospital mortality in low-to-
intermediate-risk surgical patients.17–19 There are cur-
rently three ongoing randomised controlled trials
(RCTs; SURTAVI, PARTNER IIA and UK TAVI) that are
comparing TAVI and surgical AVR in intermediate-risk
patients. The reports of these trials are eagerly awaited;
however, the long-term efﬁcacy of TAVI should not
merely be measured by equivalence at 1–5 years, but
must demonstrate at least equivalence with surgical AVR
at 10–15 years follow-up as provided in the current
report.
Strengths and limitations
Our study has three major strengths. First, we used a
prospectively maintained clinical database which is
managed by several independent database managers
who periodically check the accuracy of data entry.
Second, we had a low attrition rate with over 98% of
patients completing follow-up. Third, our clinical data-
base is linked to the ONS in the UK. This provides
accurate mortality data for individual patients as all
deaths in the UK are reported to the ONS.
Our report has four limitations. First, we did not have
a comparison group which would ideally be patients
who have undergone TAVI with long-term follow-up
data. However, at present, such data are not available.
Nevertheless, we compared our cohort survival with
operation year-matched, age-matched and gender-
matched general population. Second, we did not report
the incidence of structural valve deterioration and the
need for reoperation as these data are not readily avail-
able through our database. However, the deterioration
of survival after 8 years of follow-up may be in part indi-
cative of structural valve deterioration and the need for
reoperation. Third, we did not conduct long-term func-
tional assessment of patients which would be important
for benchmarking. Last, we did not have cause of late
mortality.
Our study highlights the need for national registries of
surgical AVR and TAVI that provide detailed information
on patient and procedural characteristics. Such registries
must be linked to national mortality data so that long-
term outcomes in patients with AS can be accurately
reported.
CONCLUSION
Long-term survival following surgical AVR in patients
over 65 years of age is excellent and is comparable to
the matched general population especially up to 8 years.
Baseline CKD, severely impaired LVF and current
smoking status are associated with a particularly poor
prognosis.
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